Top 10 Key Players in Antipyretic Drugs for Pregnant Women Market According to a newly published market research report by 24LifeSciences, global antipyretic drugs for pregnant women market was valued at USD 474 million in 2024 and is projected to reach USD 560 million by 2031, growing at a compound annual growth rate (CAGR) of 1.6% during the forecast period 2025-2031. Antipyretic drugs for pregnant women are medications specifically evaluated for relative safety during pregnancy, primarily used to reduce fever and alleviate discomfort. Maternal fever poses significant risks to fetal development, including potential neural tube defects and preterm birth, making safe fever management critically important. The market is dominated by acetaminophen (paracetamol), which remains the first-line recommended therapy due to its extensive safety profile. While growth is modest, it reflects the essential nature of this specialized segment and its stability amid broader economic fluctuations. Download a Free Sample Report (PDF): https://www.24lifesciences.com/download-sample/6529/antipyretic-drugs-for-pregnant-women-market

Global GLP-1 Agonists Market to Grow at a CAGR of 26.5% Through 2032 According to a newly published market research report by 24LifeSciences, global Glucagon Like Peptide-1 (GLP-1) Agonists market was valued at USD 75.95 billion in 2024 and is projected to reach USD 404.1 billion by 2031, growing at a compound annual growth rate (CAGR) of 26.5% during the forecast period. Glucagon-like peptide-1 (GLP-1) receptor agonists are a revolutionary class of injectable and oral medications that mimic the action of the endogenous incretin hormone GLP-1. These advanced therapeutics are primarily prescribed for the management of type 2 diabetes due to their ability to stimulate insulin secretion in a glucose-dependent manner, significantly reducing the risk of dangerous hypoglycemic events compared to older insulin secretagogues. Their profound efficacy in weight management and demonstrated cardiovascular risk reduction have fundamentally expanded their role in modern metabolic care, positioning them as one of the most significant drug classes in contemporary medicine. Download a Free Sample Report (PDF): https://www.24lifesciences.com/download-sample/6560/glucagon-like-peptide-glp-agonists-market-market

Ibuprofen API Market Outlook 2025: Supply Chain & Pricing Trends According to a newly published market research report by 24LifeSciences, global ibuprofen market was valued at USD 3.87 billion in 2024 and is projected to reach USD 4.98 billion by 2031, growing at a compound annual growth rate (CAGR) of 3.7% during the forecast period 2025–2031. Ibuprofen, a leading nonsteroidal anti-inflammatory drug (NSAID), is globally recognized for its potent analgesic, antipyretic, and anti-inflammatory properties. As an Active Pharmaceutical Ingredient (API), it serves as the foundational component in numerous over-the-counter and prescription medications designed to treat common conditions such as headaches, muscle pain, arthritis, dental pain, and fever. Its established efficacy and favorable safety profile at recommended doses continue to make it a cornerstone of global pain management strategies. Download a Free Sample Report (PDF): https://www.24lifesciences.com/download-sample/669buprofen-market-market

Expert fertility pharmacy services combine advanced medication compounding with dedicated women’s health care to support personalized treatment plans. Our pharmacy works closely with providers to deliver precise formulations, reliable medications, and ongoing patient guidance. Focused on safety, accuracy, and compassionate service, we help improve outcomes across fertility treatment and women’s wellness needs through customized pharmacy solutions designed for each individual. https://hannspharmacy.com/womens-health-and-wellness/

Global Knee Bursitis Treatment Market Size & Forecast to 2034 According to a newly published market research report by 24LifeSciences, global knee bursitis treatment market was valued at USD 821.4 million in 2024 and is projected to reach USD 1.2 billion by 2031, growing at a compound annual growth rate (CAGR) of 5.1% during the forecast period 2024–2031. Knee bursitis involves the inflammation of the small fluid-filled sacs (bursae) that cushion the bones, tendons, and muscles around the knee joint. This painful condition, often developing from repetitive pressure, acute injury, or infection, significantly impairs mobility. Treatment typically combines rest, ice, anti-inflammatory medications, physical therapy, and in severe cases, corticosteroid injections or surgical intervention. The markets expansion reflects the critical need for effective solutions to manage pain and restore function for patients worldwide. Download a Free Sample Report (PDF): https://www.24lifesciences.com/download-sample/9087/knee-bursitis-treatment-market

Aging And Medications: Older People's Health Issues

Pharmaceutical E-commerce Market Outlook 2026: Size, Trends & Key Players According to a newly published market research report by 24LifeSciences, global pharmaceutical e-commerce market is valued at USD 75.2 billion in 2026 and is projected to reach USD 185.5 billion by 2034, growing at a compound annual growth rate (CAGR) of 11.8% during the forecast period. Pharmaceutical e-commerce refers to the online sale and distribution of prescription medicines, over-the-counter (OTC) products, health supplements, and wellness items through digital platforms. This transformative channel facilitates transactions between pharmacies, distributors, and consumers via websites and mobile applications, encompassing both business-to-consumer (B2C) and business-to-business (B2B) models. The integration of telemedicine services for electronic prescription fulfillment is revolutionizing how patients access chronic and acute medications, offering unprecedented convenience and accessibility. Download a Free Sample Report (PDF): https://www.24lifesciences.com/download-sample/10357/pharmaceutical-e-commerce-market

Self-Administered Medication Market’s CAGR of 6.3%: Leaders Shaping Home Care According to a newly published market research report by 24LifeSciences, global self-administered medication market was valued at USD 185.6 billion in 2026 and is projected to reach USD 285.4 billion by 2034, growing at a compound annual growth rate (CAGR) of 6.3% during the forecast period. Self-administered medications encompass pharmaceutical products that patients can safely use without direct professional supervision, spanning various administration routes including oral tablets, subcutaneous injections, nasal sprays, and transdermal patches. This market represents a fundamental shift toward patient-centered healthcare, empowering individuals to manage chronic conditions like diabetes, rheumatoid arthritis, and hormone deficiencies conveniently at home. The growing acceptance of these therapies reflects broader trends in healthcare decentralization and patient autonomy. Download a Free Sample Report (PDF): https://www.24lifesciences.com/download-sample/8887/self-administered-medication-market

Global Generic Oncology Drugs Market Size & Growth Drivers Through 2034 According to a newly published market research report by 24LifeSciences, global generic oncology drugs market is valued at USD 35.2 billion in 2026 and is projected to reach USD 54.1 billion by 2034, growing at a compound annual growth rate (CAGR) of 6.3% during the forecast period. Generic oncology drugs are bioequivalent versions of brand-name cancer medications used after patent expirations, providing the same active ingredients, dosage, strength, and administration routes as their innovators. These drugs are broadly categorized into small molecule drugs and large molecule drugs (biosimilars), playing a critical role in making cancer treatment affordable and accessible globally. Their established efficacy and cost-effectiveness continue to underpin their importance in oncology care, particularly amid rising healthcare cost pressures. Download a Free Sample Report (PDF): https://www.24lifesciences.com/download-sample/8833/generic-oncology-drugs-market

Generic Oncology Drugs Market’s CAGR of 6.3%: Leading Companies to Watch in 2026 According to a newly published market research report by 24LifeSciences, global generic oncology drugs market is valued at USD 35.2 billion in 2026 and is projected to reach USD 54.1 billion by 2034, growing at a compound annual growth rate (CAGR) of 6.3% during the forecast period. Generic oncology drugs are bioequivalent versions of brand-name cancer medications used after patent expirations, providing the same active ingredients, dosage, strength, and administration routes as their innovators. These drugs are broadly categorized into small molecule drugs and large molecule drugs (biosimilars), playing a critical role in making cancer treatment affordable and accessible globally. Their established efficacy and cost-effectiveness continue to underpin their importance in oncology care, particularly amid rising healthcare cost pressures. Download a Free Sample Report (PDF): https://www.24lifesciences.com/download-sample/8833/generic-oncology-drugs-market